At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Mar 10, 2026 at 16:05 ET
Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year 2025 financial results, along with business updates. No financial data was released in this press release, which serves only as a notification of the forthcoming earnings event.
- Trevi Therapeutics will host a conference call on March 17, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results.
- The call will include senior management and will be webcast live; registration is required.
- No financial results or material business updates were disclosed in this release.
- The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough (RCC).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access